How many French patients are prescribed bortezomib?
Bortezomib is a standard treatment for multiple‑myeloma and mantle‑cell lymphoma. In France, it is routinely prescribed under the National Health Insurance scheme, covering roughly 12 % of the multiple‑myeloma patient population each year. That translates to about 3,000–4,000 new bortezomib prescriptions annually, according to market reports [1].
What drives sales of bortezomib in France?
The main drivers are the disease prevalence, the lack of first‑line alternatives for relapsed disease, and the reimbursement status. France’s health system classifies bortezomib as a high‑cost drug, but it receives full coverage for approved indications, encouraging physicians to prescribe it. The drug’s efficacy in extending progression‑free survival also keeps it in the treatment guidelines.
Which competitors are active in the French proteasome‑inhibitor market?
Carfilzomib (Kyprolis) and ixazomib (Ninlaro) have entered France since 2017 and 2019, respectively. These agents compete mainly in relapsed or refractory settings. However, bortezomib remains the most widely used due to its long clinical track record and lower per‑dose cost compared with carfilzomib.
Does a patent barrier still protect bortezomib in France?
The original bortezomib patent expired in the European Union in 2013, but the brand name (Velcade®) is protected under the marketing‑authorisation holder’s exclusive rights. A biosimilar version entered the French market in 2022, but it must still meet strict EU quality standards and can only be used in the same indications as the originator.
Will a biosimilar or generic enter before the next patent expiry?
The next major patent, covering the specific formulation used by the manufacturer, is set to expire in 2028. A generic version is unlikely before then. A biosimilar, however, could enter a few years earlier, subject to regulatory clearance and reimbursement negotiations.
How is bortezomib reimbursed in France?
Under the French system, the drug is reimbursed at 100 % for approved indications. Physicians must submit a justification dossier for each prescription, ensuring that the drug is used in line with national guidelines. The reimbursement rate remains stable, with the national health authority reviewing the cost‑effectiveness of new generics or biosimilars regularly.
What are the cost implications for hospitals and patients?
A typical course of bortezomib costs about €1,200 per vial. A standard six‑month regimen can reach €48,000, but this cost is fully covered by the health insurer, leaving the patient with minimal out‑of‑pocket expenses. Hospitals benefit from bulk purchasing agreements that reduce the per‑patient cost by up to 15 %.
How does the French market for bortezomib compare with other EU countries?
France holds one of the largest shares of the EU bortezomib market, with sales accounting for roughly 18 % of total European sales. The higher adoption rate is attributed to France’s strong public oncology network and a national policy that favors early access to approved therapies.
What regulatory changes could shift the French market landscape?
Upcoming EU regulations on orphan drug pricing and the introduction of a new cost‑control framework for high‑price oncology drugs could influence reimbursement and pricing negotiations. Any change may prompt the health authority to reassess the cost‑effectiveness of bortezomib relative to newer agents.
Where to find detailed sales and patent data?
For the latest figures on market share, pricing trends, and patent status, consult DrugPatentWatch.com, which provides up‑to‑date commercial and legal information on oncology drugs in France and across the EU.
Sources
[1] DrugPatentWatch.com – Bortezomib Market in France, 2024.